BackNeumora Therapeutics Overview
Neumora Therapeutics Inc.

Neumora Therapeutics Target Price

Analysts' average 12-month price target for Neumora Therapeutics is $4.5.

Get informed when a big investor buys or sells

+ Follow

Share Price

$1.6

Average Target Price

$4.50181.2% upside

2 analysts in the last 4 months

High: $5 | Low: $4

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-13RBC CapitalBrian Abrahams$5212.5% upsideOpen
2026-06-18Mizuho Securities$4150% upsideOpen
2026-01-12Leerink PartnersMarc Goodman$8400% upsideOpen
2026-01-05Mizuho SecuritiesGraig Suvannavejh$6275% upsideOpen
2025-12-01RBC Capital$7337.5% upsideOpen
2025-10-28Needham$8400% upsideOpen
2025-03-07Stifel Nicolaus$225% upsideOpen
2025-01-02RBC CapitalBrian Abrahams$4150% upsideOpen
2024-07-22NeedhamAmi Fadia$231337.5% upsideOpen
2024-07-08Mizuho SecuritiesGraig Suvannavejh$201150% upsideOpen
2024-06-17RBC CapitalBrian Abrahams$291712.5% upsideOpen
2024-03-13RBC CapitalBrian Abrahams$311837.5% upsideOpen
2023-10-10Stifel NicolausPaul Matteis$261525% upsideOpen
2023-10-10RBC CapitalBrian Abrahams$241400% upsideOpen

Neumora Therapeutics (NMRA) FAQ

Neumora Therapeutics posts a target price of $4.5. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $4.5 for NMRA means covering analysts, on average, see the stock 181.2% upside of $1.6 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for NMRA's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Neumora Therapeutics's other metric pages and overview cover the third.